Is it safe to start bupropion (Wellbutrin) in a patient with a mildly elevated total bilirubin (1.3 mg/dL) and normal AST (19 U/L), ALT (17 U/L) and low alkaline phosphatase (30 U/L)?

It is safe to start Wellbutrin (bupropion) in this patient

The mildly elevated total bilirubin (1.3 mg/dL) with completely normal transaminases (AST 19, ALT 17) does not represent a contraindication to starting bupropion, and most likely reflects Gilbert's syndrome rather than hepatocellular dysfunction.

Clinical Assessment

Your patient's liver profile shows:

• Total bilirubin 1.3 mg/dL (mildly elevated)
• AST 19 U/L and ALT 17 U/L (normal, well below any concerning threshold)
• Alkaline phosphatase 30 U/L (low, but not clinically significant)

This pattern—isolated hyperbilirubinemia with normal transaminases—is the hallmark of Gilbert's syndrome, which affects 5-10% of the population 1. Gilbert's syndrome is characterized by unconjugated (indirect) hyperbilirubinemia with total bilirubin rarely exceeding 4-5 mg/dL, and importantly, it does not represent true hepatocellular disease 1.

Key Diagnostic Step Before Starting Treatment

Obtain a direct (conjugated) bilirubin level to confirm Gilbert's syndrome. In Gilbert's syndrome, the conjugated bilirubin should be less than 20-30% of the total bilirubin 1. If the direct bilirubin is >35% of total bilirubin, this would suggest hepatocellular injury rather than Gilbert's syndrome 1.

Why This Patient Can Safely Start Bupropion

The critical safety concern with bupropion is drug-induced liver injury (DILI), which occurs in only 0.1-1% of treated patients 2. Bupropion-induced hepatotoxicity typically presents as:

• Hepatocellular pattern: Marked elevation of ALT/AST (often >3-5× ULN)
• Cholestatic pattern: Elevated alkaline phosphatase and direct bilirubin
• Onset: Usually 1-6 weeks after starting treatment 2, 3, 4

Your patient has none of these features at baseline. The normal transaminases indicate no hepatocellular dysfunction, and the low alkaline phosphatase rules out cholestasis.

Monitoring Strategy After Starting Bupropion

While baseline liver tests are not routinely required before starting bupropion per FDA labeling 5, given this patient's baseline bilirubin elevation, implement the following monitoring:

Initial Phase (First 6 Weeks)

• Educate the patient to report immediately: jaundice, severe fatigue, nausea, vomiting, right upper quadrant pain, or pruritus 6
• Repeat liver panel at 2-4 weeks: ALT, AST, alkaline phosphatase, total and direct bilirubin
• Stop bupropion immediately if:
  • ALT or AST rises to ≥3× ULN with symptoms 7
  • ALT or AST rises to ≥5× ULN even without symptoms 7
  • Direct bilirubin doubles from baseline 7

Ongoing Monitoring

• If liver tests remain stable at 2-4 weeks, no routine monitoring is required 5
• The patient should maintain awareness of hepatotoxicity symptoms throughout treatment

Common Pitfalls to Avoid

1. Do not withhold bupropion based solely on isolated mild hyperbilirubinemia with normal transaminases—this likely represents benign Gilbert's syndrome, not liver disease 1

2. Do not confuse "direct" and "conjugated" bilirubin—direct bilirubin includes both conjugated bilirubin and delta bilirubin (albumin-bound), which can persist longer 1

3. Do not misattribute future bilirubin fluctuations to drug toxicity if Gilbert's syndrome is confirmed—these patients have intermittent unconjugated hyperbilirubinemia that varies independently of medications 1

4. Recognize that bupropion hepatotoxicity, when it occurs, typically manifests with elevated transaminases, not isolated bilirubin elevation 2, 3, 4

Clinical Context

Bupropion-induced hepatotoxicity is rare but well-documented, with cases showing dramatic transaminase elevations (up to 68-fold normal) and often a hypersensitivity pattern with fever, rash, or eosinophilia 2, 3, 4. However, these cases uniformly showed marked transaminase elevation, not isolated bilirubin changes. Your patient's normal baseline transaminases provide reassurance that hepatocellular function is intact.

The low alkaline phosphatase (30 U/L) is not clinically concerning and does not predict adverse outcomes or contraindicate bupropion use.